Evaluation of Genetically Inactivated Alpha Toxin for Protection in Multiple Mouse Models of Staphylococcus aureus Infection

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Brady, Rebecca A ^a   Mocca, Christopher P ^a   Prabhakara, Ranjani ^a   Plaut, Roger D ^a   Shirtliff, Mark E ^b,c   Merkel, Tod J ^a   Burns, Drusilla L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOXIN; HLAH35L VACCINE; IMMUNOLOGICAL ADJUVANT; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; LIVE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BIOFILM; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; GROWTH INHIBITION; IMMUNIZATION; MOUSE; NONHUMAN; SKIN INFECTION; SKIN PROTECTION; SKIN SOFT TISSUE INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; ANIMAL; BACTERIAL COUNT; DISEASE MODEL; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MICROBIOLOGY; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BIOFILMS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINES, ATTENUATED;

EID: 84876920391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063040     Document Type: Article

References (46)

1. Krespi YP, Kizhner V, (2012) Laser-assisted nasal decolonization of Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. Am J Otolaryngol 33: 572-575.
2. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, et al. (2007) Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States. JAMA 298: 1763-1771.
3. Gorwitz RJ, Kruszon-Moran D, McAllister SK, McQuillan G, McDougal LK, et al. (2008) Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 197: 1226-1234.
4. Peacock SJ, de Silva I, Lowy FD, (2001) What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 9: 605-610.
5. von Eiff C, Becker K, Machka K, Stammer H, Peters G, (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 344: 11-16.
6. Foster TJ, (2004) The Staphylococcus aureus "superbug". J Clin Invest 114: 1693-1696.
7. Resch A, Rosenstein R, Nerz C, Gotz F, (2005) Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions. Appl Environ Microbiol 71: 2663-2676.
8. Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, et al. (2004) Global gene expression in Staphylococcus aureus biofilms. J Bacteriol 186: 4665-4684.
9. Resch A, Leicht S, Saric M, Pasztor L, Jakob A, et al. (2006) Comparative proteome analysis of Staphylococcus aureus biofilm and planktonic cells and correlation with transcriptome profiling. Proteomics 6: 1867-1877.
10. Arrecubieta C, Matsunaga I, Asai T, Naka Y, Deng MC, et al. (2008) Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. J Infect Dis 198: 571-575.
11. Brouillette E, Lacasse P, Shkreta L, Belanger J, Grondin G, et al. (2002) DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 20: 2348-2357.
12. Cheng AG, McAdow M, Kim HK, Bae T, Missiakas DM, et al. (2010) Contribution of coagulases towards Staphylococcus aureus disease and protective immunity. PLoS Pathog 6: e1001036.
13. Gong R, Hu C, Xu H, Guo A, Chen H, et al. (2010) Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice. Clin Vaccine Immunol 17: 1746-1752.
14. Hu DL, Narita K, Hyodo M, Hayakawa Y, Nakane A, et al. (2009) c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection. Vaccine 27: 4867-4873.
15. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T, (2001) Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572-1580.
16. Josefsson E, Higgins J, Foster TJ, Tarkowski A, (2008) Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 3: e2206.
17. Mamo W, Boden M, Flock JI, (1994) Vaccination with Staphylococcus aureus fibrinogen binding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis model. FEMS Immunol Med Microbiol 10: 47-53.
18. Schaffer AC, Solinga RM, Cocchiaro J, Portoles M, Kiser KB, et al. (2006) Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74: 2145-2153.
19. Shannon O, Uekotter A, Flock JI, (2006) The neutralizing effects of hyperimmune antibodies against extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus. Scand J Immunol 63: 184-190.
20. Shkreta L, Talbot BG, Diarra MS, Lacasse P, (2004) Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 23: 114-126.
21. Zhou H, Xiong ZY, Li HP, Zheng YL, Jiang YQ, (2006) An immunogenicity study of a newly fusion protein Cna-FnBP vaccinated against Staphylococcus aureus infections in a mice model. Vaccine 24: 4830-4837.
22. Anderson AS, Scully IL, Timofeyeva Y, Murphy E, McNeil LK, et al. (2012) Staphylococcus aureus transporter MntC is a highly conserved cell surface protein that elicits protective immunity against both S. aureus and Staphylococcus epidermidis. J Infect Dis 205: 1688-1696.
23. Brady RA, O'May GA, Leid JG, Prior ML, Costerton JW, et al. (2011) Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun 79: 1797-1803.
24. Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, et al. (2006) Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193: 1098-1108.
25. Glowalla E, Tosetti B, Kronke M, Krut O, (2009) Proteomics-based identification of anchorless cell wall proteins as vaccine candidates against Staphylococcus aureus. Infect Immun 77: 2719-2729.
26. Ster C, Beaudoin F, Diarra MS, Jacques M, Malouin F, et al. (2010) Evaluation of some Staphylococcus aureus iron-regulated proteins as vaccine targets. Vet Immunol Immunopathol 136: 311-318.
27. Stranger-Jones YK, Bae T, Schneewind O, (2006) Vaccine assembly from surface proteins of Staphylococcus aureus. Proceedings of the National Academy of Sciences 103: 16942-16947.
28. Joshi A, Pancari G, Cope L, Bowman E, Cua D, et al. (2012) Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother 8: 336-346.
29. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O, (2010) Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207: 1863-1870.
30. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, et al. (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202: 1050-1058.
31. Narita K, Hu DL, Tsuji T, Nakane A, (2008) Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection. FEMS Immunol Med Microbiol 52: 389-396.
32. Bubeck Wardenburg J, Schneewind O, (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205: 287-294.
33. Gening ML, Maira-Litran T, Kropec A, Skurnik D, Grout M, et al. (2010) Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun 78: 764-772.
34. Cook J, Hepler R, Pancari G, Kuklin N, Fan H, et al. (2009) Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection. Hum Vaccin 5: 254-263.
35. Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ, (2006) Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine. Hum Vaccin 2: 89-98.
36. Menzies BE, Kernodle DS, (1994) Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun 62: 1843-1847.
37. Rauch S, Dedent AG, Kim HK, Bubeck Wardenburg J, Missiakas DM, et al. (2012) Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect Immun 80: 3721-3732.
38. Adhikari RP, Karauzum H, Sarwar J, Abaandou L, Mahmoudieh M, et al. (2012) Novel Structurally Designed Vaccine for S. aureus alpha-Hemolysin: Protection against Bacteremia and Pneumonia. PLoS One 7: e38567.
39. Hume EB, Dajcs JJ, Moreau JM, O'Callaghan RJ, (2000) Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect Immun 68: 6052-6055.
40. Mandel M, Higa A, (1970) Calcium-dependent bacteriophage DNA infection. J Mol Biol 53: 159-162.
41. Stemmer WP, Morris SK, (1992) Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis. Biotechniques 13: 214-220.
42. Prabhakara R, Foreman O, De Pascalis R, Lee GM, Plaut RD, et al. (2013) An Epicutaneous Model of Community-Acquired Staphylococcus aureus Skin Infections. Infect Immun: Epub 4 Feb 2013.
43. Prabhakara R, Harro JM, Leid JG, Harris M, Shirtliff ME, (2011) Murine immune response to a chronic Staphylococcus aureus biofilm infection. Infect Immun 79: 1789-1796.
44. Li D, Gromov K, Soballe K, Puzas JE, O'Keefe RJ, et al. (2008) Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and humoral immunity. J Orthop Res 26: 96-105.
45. Ohlsen K, Lorenz U, (2010) Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol 300: 402-410.
46. Brady RA, Leid JG, Camper AK, Costerton JW, Shirtliff ME, (2006) Identification of Staphylococcus aureus proteins recognized by the antibody-mediated immune response to a biofilm infection. Infect Immun 74: 3415-3426.